Skip to content

Main Navigation

  • About us
    • Our team
    • Employee stories
    • Working with us
    • Our principles
    • Mission, vision & values
    • History
    • Corporate Social Responsibility
  • Science & Services
    • Contexts of use
      • Trial design and analyses
      • Program strategies and efficiencies
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK & PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientist
      • Expert Advice
      • Training workshop
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence & Biosimilarity
    • Publications
    • Case studies
    • Academic collaborations
  • Careers
  • Events
  • News
  • Contact us
  • LinkedIn

Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients with Acquired Thrombotic Thrombocytopenic Purpura, PB2249

HemaSphere. 2019 Jun;3(S1):1007.
Sargentini L, Hansson E, Bergstrand M, Callewaert F, Sousa RP.
HematologyJournalMIDDPharmacometricsSpecial/specific populations

Pharmetheus Affiliates

Portrait-of-Emma-Hansson_Pharmetheus
Senior Consultant, Regulatory Affairs

Emma Hansson

See bio
Portrait-of-Martin-Bergstrand_Pharmetheus
Principal Consultant & MIDD Platform Scientific Lead

Martin Bergstrand

See bio

Contact

Pharmetheus AB
Kungsängstull 4
753 19 Uppsala, Sweden

Visiting address: Dragarbrunnsgatan 77, 5th floor

info@pharmetheus.com

+46(0)18-51 33 28

Links

  • Home
  • Newsletter
  • LinkedIn
  • Whistleblower
  • Privacy Policy
  • Cookie Policy
  • Consent Preferences

Services

  • Contexts of use
  • Pharmetheus platforms
  • Solutions
  • Case studies
  • Publications

About

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.